Amgen Revives Drug Thanks to Biomarker Data
May 24, 2012, 02:00 AM
by
Michael Croft
Bloomberg | In light of a small set of data, Amgen is reviving its gastric cancer drug rilotumumab that seems to show efficacy for patients with high levels of c-Met, a protein linked to cancer growth. The revival is a win for personalized medicine.
May 24, 2012 | In light of a small set of data, Amgen is reviving its gastric cancer drug rilotumumab that seems to show efficacy for patients with high levels of c-Met, a protein linked to cancer growth. The revival is a win for personalized medicine, and the company will launch a late-stage trial of the drug for those patients. Bloomberg